Exploring Erenumab's Efficacy and Safety for Migraine Prevention in Real-World Settings: A Systematic Review.

Autor:	Nisar MR; Neurology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Kotha R; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Saad-Omer SI; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Singh S; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Olayinka OT; Clinical Sciences, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Orelus J; Emergency Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Yu AK; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jul 28; Vol. 16 (7), pp. e65571. Date of Electronic Publication: 2024 Jul 28 (Print Publication: 2024).
DOI:	10.7759/cureus.65571
Abstrakt:	Migraine causes debilitating headaches and significantly impacts quality of life. Effective migraine-specific treatments have been lacking until the advent of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) receptors, which have expanded therapy options for migraine treatment. This study explores the short- and long-term efficacy and safety of erenumab in migraine treatment. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 criteria guided this systematic review. Five databases - PubMed, PubMed Central, Google Scholar, ScienceDirect, and Sage Journal - were searched for published, freely accessible, full-text articles in English from the past five years. Eligible patients included those with episodic or chronic migraines who received erenumab intervention. From an initial search yielding 680 relevant studies, 12 prospective observational cohort studies were selected after assessing the risk of bias through the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. All included studies demonstrated a significant reduction in monthly migraine days (MMDs) by the end of the treatment period, with mild adverse effects observed. No significant short-term or long-term safety concerns were identified. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Nisar et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu